Skip to main content

Table 2 Clinical parameters

From: Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia

 

Control

MEM

MEM + AMK

p-value

Temperature (°C)

38.3 ± 0.7

38.3 ± 0.6

38.1 ± 0.6

0.06

Tracheal secretions

 Quantity

2 (1–3)

1 (0–1)*

1 (0–1)†

 < 0.001

 Purulent (%)

100

98.4

94.6

0.11

WBC (109/L)

13.3 (8.6–30.2)

16.0 (10.4–24.0)

13.6 (7.5–23.7)

0.91

Hemoglobin (g/L)

9.2 ± 0.9

9.4 ± 1.1

7.9 ± 1.4†, ‡

 < 0.001

Platelets (109/L)

313.3 ± 125.6

272.0 ± 104.0

249.4 ± 142.2

0.07

Creatinine (mg/dL)

1.00 (0.90–1.09)

1.07 (0.94–1.25)*

1.07 (1.01–1.22)†

0.017

PT (sec)

11.4 (10.5–12.0)

11.8 (10.5–13.8)

11.3 (10.5–12.4)

0.28

  1. Data are reported as means ± standard deviations or as medians (interquartile range) for normally and non-normally distributed parameters, respectively. The PT reference range is 9–12 s in pigs
  2. AMK, inhaled amikacin; MEM, IV meropenem; PT, prothrombin time; PTT, thromboplastin time
  3. Post hoc analysis with Bonferroni correction: *p < 0.05 control versus MEM
  4. †p < 0.05 control versus MEM + AMK
  5. ‡p < 0.05 MEM versus MEM + AMK